Information Provided By: 
Fly News Breaks for August 26, 2019
IOVA
Aug 26, 2019 | 08:30 EDT
Jefferies analyst Biren Amin views the recent pullback in shares of Iovance Biotherapeutics as a buying opportunity into the end of 2019. After meeting with management, the analyst believes the melanoma and cervical pivotal cohorts appear to be enrolling patients with Iovance on track toward finishing patient enrollment in the melanoma study in Q1 of 2020. He thinks there is some likelihood of data at SITC in November and keeps a Buy rating on the shares with a $33 price target.
News For IOVA From the Last 2 Days
There are no results for your query IOVA
